BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Genetown

  Unum Therapeutics Announces Presentation of Initial Clinical Data from the ATTCK-20-2 Trial and Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the Upcoming 59th ASH Annual Meeting

  The oral presentation will highlight early data from an ongoing Phase I dose escalation study, ATTCK-20-2 (ClinicalTrials.gov No. NCT02776813), of ACTR087 used in combination with rituximab in subjects with relapsed/refractory CD20+ B cell Non-Hodgkin lymphoma.

  November 1, 2017

   · 

  5 min read
• Business

  GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017

  GlycoMimetics announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results on Wednesday, November 8, 2017, at 8:30 a.m. ET.

  November 1, 2017

   · 

  1 min read
• Genetown

  Magenta Therapeutics to Present Clinical Results and Preclinical Research at of ASH Annual Meeting

  Magenta Therapeutics announced that the Company will present clinical data from its stem cell expansion program and insights into its preclinical research at the 59th annual meeting of the ASH.

  November 1, 2017

   · 

  3 min read
• Drug Development

  Nordic Nanovector: Updated Results From Phase I/II Trial of Betalutin in Non-Hodgkin Lymphoma to be Presented at ASH in December

  The dataset includes 55 evaluable patients. Data from patients receiving the two most promising dosing regimens in the Phase II expansion cohorts

  November 1, 2017

   · 

  6 min read
• Genetown

  Eleven Biotherapeutics Prices of $8M Underwritten Public Offering

  Eleven Biotherapeutics announced the pricing of an underwritten public offering of 5,525,000 shares of its common stock.

  November 1, 2017

   · 

  5 min read
• Drug Development

  Novartis Presents Data at ASH for Patients With Serious Blood Disorders Like Lymphoma, Leukemia and Sickle Cell Disease

  The 59th American Society of Hematology Annual Meeting & Exposition will be held in Atlanta on December 9-12.

  November 1, 2017

   · 

  12 min read
• Business

  Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017

  Management will host a conference call and live audio webcast to discuss the results and provide a general corporate update

  November 1, 2017

   · 

  1 min read
• Drug Development

  Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor

  Phase 1b/2a clinical trial combines Regeneron’s PD-1 inhibitor cemiplimab and Inovio’s T cell activator INO-5401 in brain cancer.

  November 1, 2017

   · 

  6 min read
• Business

  Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results

  The CEO and CFO will host a conference call and webcast at 4:30 p.m. ET on November 8, 2017 to discuss these results.

  November 1, 2017

   · 

  3 min read
• Policy

  Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients With ALS

  Biohaven and its wholly owned subsidiary, Biohaven Pharma, today announced that the FDA has notified the Company that it may proceed with its clinical investigation of sublingual BHV-0223 as a potential treatment for patients with ALS.

  November 1, 2017

   · 

  6 min read